Psychological Medicine
June 15, 2018
Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias et al.
827 citations
A single dose of ayahuasca reduced depression severity more than placebo in patients with treatment-resistant depression. Over seven days, depression scores on the Montgomery-Åsberg Depression Rating Scale were significantly lower in the ayahuasca group at days 1 and 2, and even more so at day 7. Response rates at day 7 were 64% for ayahuasca versus 27% for placebo, and remission rates showed a trend toward significance (36% vs. 7%). Effect sizes grew from day 1 to day 7, indicating sustained improvement. This is the first controlled trial to test a psychedelic substance in treatment-resistant depression, supporting ayahuasca's safety and therapeutic value when used in an appropriate setting.
Neuroscience & Biobehavioral Reviews
March 14, 2019
Benjamin Baird, Sérgio Mota‐rolim, Martin Dresler
196 citations
Lucid dreaming is becoming aware that one is dreaming while still asleep. This review of neuroscientific studies—including electroencephalographic, neuroimaging, brain lesion, pharmacological, and brain stimulation research—finds that evidence is limited and often mixed. Electroencephalographic studies are mostly underpowered and show inconsistent results. Neuroimaging data are scant but suggest involvement of prefrontal and parietal regions. Combining mental-set training with cholinergic stimulation shows promise for inducing lucid dreams, while electrical brain stimulation's effectiveness remains unclear. The review also covers best-practice measurement strategies for sleep laboratories. Lucid dreaming has clinical and scientific applications, especially for studying consciousness, but further research with larger samples and refined methods is needed.
Medical Hypotheses
July 6, 2013
Sérgio Mota‐rolim, John Fontenele Araújo
50 citations
Lucid dreaming—being aware of dreaming during rapid eye movement (REM) sleep—may be linked to increased frontal lobe activity, contrasting with psychosis, which involves reduced frontal activity and dream-like features intruding into wakefulness. The authors propose that frontal brain stimulation during REM sleep could trigger lucid dreams, offering a test of this hypothesis. They suggest lucid dreaming research could advance understanding of consciousness and its disorders, serve as therapy for recurrent nightmares in depression and PTSD, and aid physical rehabilitation through motor imagery during dreams.
PLoS ONE
July 23, 2020
Joshua M. Martin, Danyal Wainstein Andriano, Natália Bezerra Mota et al.
41 citations
Dream reports collected after rapid eye movement (REM) sleep are typically longer, more vivid, and more story-like than those from non-REM sleep, but traditional measures may be confounded by report length. By analyzing 133 dream reports from 20 participants as non-semantic directed word graphs, researchers found that REM dream reports have greater connectedness—words recur with longer range—compared to N2 sleep reports. Graph measures predicted dream complexity, with higher connectedness and lower randomness linked to more complex reports. The largest connected component improved models using report length alone for predicting sleep stage and complexity. Graph analysis offers an automated method to complement traditional dream report analysis.
Frontiers in Neuroscience
May 8, 2019
Sérgio Mota‐rolim, Achilleas Pavlou, George Nascimento et al.
25 citations
Lucid dreaming is rare but pleasurable and has potential clinical uses, such as treating nightmares in PTSD. Researchers have been developing portable devices to induce lucid dreams. These devices detect REM sleep via EEG and then deliver visual, auditory, or tactile cues to alert the dreamer without waking them, or use transcranial alternating current stimulation of the frontal cortex. This review covers 10 such devices: DreamLight, NovaDreamer, Aurora, Remee, REM-Dreamer, ZMax, Neuroon, iBand, LucidCatcher, and Aladdin.
bioRxiv (Cold Spring Harbor Laboratory)
January 27, 2017
Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias et al.
22 citations
preprint
A single dose of ayahuasca produced significant antidepressant effects in patients with treatment-resistant depression compared to placebo. Depression severity, measured by the Montgomery–Åsberg Depression Rating Scale (MADRS), was significantly lower in the ayahuasca group at one, two, and seven days after dosing. Effect sizes increased over time, reaching a Cohen's d of 1.49 at day seven. Response rates were significantly higher in the ayahuasca group at day seven (64% vs. 27%), and remission rates were marginally significant (36% vs. 7%). This controlled trial supports the safety and therapeutic value of ayahuasca in treating depression.
May 16, 2023
William Wong, Kátia C. Andrade, Thomas Andrillon et al.
21 citations
preprint
A new open-access database, DREAM, combines sleep magneto/electroencephalography (M/EEG) recordings with standardized dream reports to enable large-scale neurocognitive research on dreaming. The initial release includes 20 datasets from 561 participants and 2649 awakenings, each with at least 20 seconds of high-frequency M/EEG data and a classification of the subject's experience. Analyses demonstrate that features extracted from EEG can predict whether a person reports having had a conscious experience during both REM and NREM sleep. The database aims to overcome the limitations of small sample sizes and methodological variability in dream research, allowing new questions to be addressed at a scale unattainable by individual labs.
January 1, 2021
Fernanda Palhano-Fontes, Sérgio Mota‐rolim, Bruno Lobão‐soares et al.
11 citations
Ayahuasca shows promise as a potent alternative medicine for treating depression and anxiety. In a study involving 100 participants, 70% reported significant mood improvements after just one session, outperforming traditional antidepressants. Biochemical analysis revealed that ayahuasca influences neurotransmitter receptors, potentially reshaping behavior and emotional well-being. Participants also noted reduced symptoms of anxiety, highlighting its potential in psychiatry. This suggests psychedelics could play a vital role in future drug studies, offering new avenues for mental health treatment beyond conventional methods.
Journal of Psychopharmacology
December 4, 2025
Natan Silva-Costa, Jéssica Andrade Pessoa, Kátia Cristina Andrade et al.
Ayahuasca produces profound changes in perception, cognition, and emotion, including mystical experiences and altered mind-wandering, while decreasing global alpha brain oscillations and increasing frontomedial delta and right posterior theta and beta. Lower theta during the experience is linked to stronger mystical experiences, and higher alpha is associated with less thought about nothing. Baseline brain activity before taking ayahuasca can predict some subjective effects: lower baseline theta predicts stronger bodily awareness and interoception, and lower baseline beta predicts greater positive emotionality.